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ABSTRACT: Extended N4-(3-arylpropyl)oxy derivatives of uridine-5′-triphosphate were synthesized and potently stimulated
phospholipase C stimulation in astrocytoma cells expressing G protein-coupled human (h) P2Y receptors (P2YRs) activated by
UTP (P2Y2/4R) or UDP (P2Y6R). The potent P2Y4R-selective N
4-(3-phenylpropyl)oxy agonist was phenyl ring-substituted or
replaced with terminal heterocyclic or naphthyl rings with retention of P2YR potency. This broad tolerance for steric bulk in a
distal region was not observed for dinucleoside tetraphosphate agonists with both nucleobases substituted. The potent N4-(3-(4-
methoxyphenyl)-propyl)oxy analogue 19 (EC50: P2Y2R, 47 nM; P2Y4R, 23 nM) was functionalized for chain extension using
click tethering of fluorophores as prosthetic groups. The BODIPY 630/650 conjugate 28 (MRS4162) exhibited EC50 values of
70, 66, and 23 nM at the hP2Y2/4/6Rs, respectively, and specifically labeled cells expressing the P2Y6R. Thus, an extended N
4-(3-
arylpropyl)oxy group accessed a structurally permissive region on three Gq-coupled P2YRs, and potency and selectivity were
modulated by distal structural changes. This freedom of substitution was utilized to design of a pan-agonist fluorescent probe of a
subset of uracil nucleotide-activated hP2YRs.
■ INTRODUCTION
The P2Y receptors (P2YRs) are G protein-coupled receptors
(GPCRs) that are activated by extracellular nucleotides.1 The
widely expressed2 UTP-activated (P2Y2R and P2Y4R) and
UDP-activated (P2Y6R) receptors belong to the subfamily of
P2Y1-like receptors that promote inositol lipid signaling
through Gq-mediated activation of phospholipase C-β (PLC-
β). Few selective agonists and antagonists3 are available for
pharmacological differentiation of these uracil nucleotide-
regulated receptors, and P2Y2R, P2Y4R, and P2Y6R exhibit
much overlap in affinities for pyrimidine nucleotides. This study
was initiated to synthesize nucleoside 5′-triphosphate deriva-
tives as potent agonist probes of the P2Y4R, including chain
derivatization for incorporation of bulky reporter groups. The
message for this P2YR subtype is expressed at high levels in
intestine, pituitary, and brain, with lower levels observed in
adipose tissue, prostate, spleen, lymphocytes, skeletal muscle,
and lung.2,3 The P2Y4R has been shown to regulate
cardiovascular development,4 and activation of this signaling
protein results in intestinal chloride secretion,5 inhibition of
contraction of the mouse ileum longitudinal muscle, and K+
secretion in the luminal membrane of the distal colon.6,7
Postsynaptic P2Y4Rs are expressed on neurons of the rat
hypothalamus that release neuropeptides.8 Thus, ligands of the
P2Y4R are of potential interest for pharmacotherapies directed
at intestinal function, angiogenesis, cardiac remodeling,
postischemic revascularization, CNS function, and inflamma-
tion.4,9
Uridine-5′-triphosphate (UTP, 1) is the endogenous P2Y4R
agonist (EC50 = 80 nM),
1,10 while adenosine-5′-triphosphate
(ATP) antagonizes the human homologue of this receptor and
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activates the rat homologue.11 Structure−activity relationship
(SAR) studies of the P2Y4R have been performed through
preparation of modified analogues in conjunction with
molecular modeling. Two analogues of UTP, N4-(3-
Chart 1. Structures of Pyrimidine Nucleotides As Prototypical Agonist Ligands for Studying the P2Y4R
a
aEC50 values for activation of PLC via the human P2Y4R are: 2, 23 nM; 2′-azido-2′-deoxy-UTP 3, 1100 nM; iso-CMP 4, 4980 nM.11−13
Table 1. Potency of a Series of Pyrimidine Nucleotide Derivatives at Three Subtypes of hP2YRs
potency, EC50 (nM)





5b N-O-CH3 28 ± 4 25 ± 3 130 ± 21
6b N-O-CH2CH3 817 ± 93 210 ± 79 877 ± 50
7 N-O-(CH3)3CO2H 299 ± 56 470 ± 130 697 ± 167
8b N-O-CH2Ph 620 ± 75 97 ± 14 230 ± 37
9b N-O-(CH2)2Ph 1200 ± 270 73 ± 17 1210 ± 220
2b N-O-(CH2)3Ph 640 ± 147 23 ± 4 740 ± 29
10 N-O-(CH2)4Ph 214 ± 11 54 ± 14 251 ± 110
11 N-O-(CH2)2O-Ph 3400 ± 880 430 ± 93 1780 ± 430
12 N-O-(CH2)3-3-F-Ph 190 ± 28 100 ± 22 539 ± 28
13 N-O-(CH2)3-4-F-Ph 547 ± 125 105 ± 27 1210 ± 290
14 N-O-(CH2)3-4-Br-Ph 350 ± 70 141 ± 60 225 ± 39
15 N-O-(CH2)3-3-I-Ph 325 ± 100 114 ± 13 299 ± 10
16 N-O-(CH2)3-4-I-Ph 187 ± 61 91 ± 15 90 ± 13
17 N-O-(CH2)3-3-NO2-Ph 457 ± 11 95 ± 25 9700 ± 1500
18 N-O-(CH2)3-4-NO2-Ph 458 ± 145 84 ± 24 1330 ± 290
19c N-O-(CH2)3-4-CH3O-Ph 47 ± 2 23 ± 8 277 ± 75
20 N-O-(CH2)3-3-pyridyl 327 ± 77 300 ± 230 2950 ± 1020
21 N-O-(CH2)3-4-pyridyl 285 ± 20 250 ± 160 4280 ± 1330
22 N-O-(CH2)3-3-thienyl 103 ± 7 20 ± 2 164 ± 48
23 N-O-(CH2)3CCH 168 ± 30 410 ± 28 3000 ± 1500
24 N-O-(CH2)3-(2-naphthyl) 139 ± 29 128 ± 26 90 ± 12
25 N-O-(CH2)2-C(CN)(Ph)2 934 ± 92 47 ± 13 177 ± 21
26 N-O-(CH2)3-Ph-(4-O-CH2CONH-(CH2)2CCH 109 ± 33 40 ± 14 183 ± 42
27 Alexa Fluor 488 derivative 577 ± 146 200 ± 42 334 ± 36
28 BODIPY 630/650 derivative 66 ± 17 70 ± 21 23 ± 7
potency, EC50 (nM)





29b,c O O 210 ± 30 130 ± 10 1160 ± 420
30 N-O-(CH3)3Ph O 389 ± 114 93 ± 19 332 ± 80
31 N-O-(CH3)3Ph N-O-(CH3)3Ph >10000 1330 ± 100 >10000
aFunctional assays were conducted with 1321N1 astrocytoma cells expressing recombinant hP2Y2, P2Y4, or P2Y6Rs. Values are expressed as the
mean ± SEM. bData from Maruoka et al.10 c29, Up4U.
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phenylpropyloxy)cytidine-5′-triphosphate, 2, and 2′-azido-2′-
deoxy-UTP, 3, and one 5′-monophosphate derivative, iso-CMP
4,10,12,13 have demonstrated (Chart 1) low to moderate
selectivity for this subtype, but highly potent and selective
P2Y4R agonists have not been identified to date.
10−16 The 4-
benzyloxyiminopyrimidine group was identified as a structurally
permissive site for synthesis of functionalized congeners,17
leading to high affinity molecular probes for the closely related
UDP-activated P2Y6R.
14 Because of the structural similarity of
the P2Y4R and P2Y6R, we focused on the same site for
derivatization of analogues of 1 that included an elongated alkyl
chain, i.e., a N4-phenylpropyloxy group, which we hypothesized
would be more suitable for conferring P2Y4R selectivity.
10 One
goal of these studies was to generate an analogue(s) with
tolerance for steric bulk when bound to the receptor,
potentially allowing attachment of a fluorophore or other
reporter group to serve as a tracer for the receptor on live cells.
This approach has been validated for adenosine receptors and
other GPCRs.18,19
■ RESULTS
We considered a 4-arylalkyloxyimino group in the pyrimidine
nucleobase as an approach to expand the range of potent
agonists of P2Y4R and related P2YRs. In summary, we have
modified the 4-(3-phenylpropyloxy)imino group of 2 with
various ring substitutions and chain elongations and evaluated
the new nucleotide derivatives in functional assays of the
hP2Y4R, P2Y6R, and P2Y2R. Because dinucleoside tetraphos-
phates are also known to activate the P2Y4R,
10 we included
several derivatives in the dinucleotide series to test their
compatibility with 4-alkyloxyimino modifications.
Novel nucleotide derivatives 7, 10−28, and 30−31 (Table 1)
were prepared and purified to homogeneity. Two series of
nucleotide derivatives were chosen: 5′-triphosphates related to
UTP and dinucleotides related to Up4U 29, which have
Scheme 1. Synthesis of Various 4-Alkoxyiminopyrimidine Ribonucleoside 5′-Triphosphatesa
aReagents and conditions: (a) cytidine, pyridine, 110 °C; (b) proton sponge, POCl3, PO(OMe)3, tributylammonium pyrophosphate, DMF; (c) 1 N
NaOH, THF, 50 °C; (d) PyBOP, DIEA, but-4-yn-1-amine.
Scheme 2. Synthesis of 4-Alkoxyiminopyrimidine Dinucleoside Tetraphosphatesa
aReagents: (a) DIC, MgCl2, DMF.
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relatively high potency at both P2Y2R and P2Y4R. The
synthetic routes to these groups of structurally modified
pyrimidine nucleotides include: UTP analogues containing a
N4-alkoxy group (Scheme 1), modified Up4U dinucleotide
analogues (Scheme 2), and UTP analogues containing Alexa
Fluor 488 and BODIPY 630/650 fluorescent dyes19,27 (Scheme
3).
The synthesis of N4-alkoxy cytidines 10−26 from cytidine
was performed using corresponding alkoxyamine hydro-
chlorides. Various alkoxy groups including phenyl, pyridyl,
thienyl, naphthyl, and alkyl ester derivatives were chosen. These
alkoxyamine derivatives were synthesized from the correspond-
ing 3-arylpropyl bromides using Gabriel synthesis or a variation
thereof using N,N′-di-tert-butoxycarbonylhydroxylamine as the
source of the hydroxylamine moiety.22,25 The 3-alkylpropyl
bromides 56−62 and 67 were synthesized from the
corresponding benzyl bromides by homologation in four
steps (Scheme 4A).23 The 3-arylpropyl bromides 73, 76, and
78 were synthesized from the corresponding alcohols and
converted to the alkyoxyimino derivatives (Scheme 4B).22 (3-
Thien-3-yl)propyl bromide 71 was synthesized from the
corresponding α,β-unsaturated carboxylic acid (Scheme S1,
Supporting Information). The resulting N4-alkoxy-cytidines
were phosphorylated by standard methods10 to give the desired
N4-alkoxy-cytidine 5′-triphosphates 10−26 (Scheme 1). In
each case, the unprotected nucleoside was first treated with
phosphorus oxychloride and the reaction mixture was treated
immediately with bis(tri-n-butylammonium) pyrophosphate to
produce the 5′-triphosphate. The synthesis of dinucleoside
tetraphosphates, including an asymmetrically substituted
analogue 30, was performed using N,N′-diisopropylcarbodii-
mide (DIC) as a coupling reagent for condensing a 5′-
monophosphate and 5′-triphosphate in the presence of
magnesium chloride (Scheme 2), which dramatically increased
the reactivity compared to carbodiimide alone.24 The
fluorescent Alexa Fluor 488 5′-triphosphate 27 and BODIPY
5′-triphosphate 28 derivatives were synthesized from alkyne
nucleotide precursor 26 and an azide derivative (e.g., a
BODIPY 630/650 azide 124 for product 28, Scheme S2,
Supporting Information) using copper-catalyzed [2 + 3]
cycloaddition click reactions with azides (Scheme 3).20
The newly synthesized analogues were tested for potency
against the P2Y2R, P2Y4R, and P2Y6R.
13−15 Similar N4-3-
phenylalkyloxy derivatives were shown to be only weakly active
at the P2Y14R;
10 thus, this subtype was not part of the initial
screen. The potencies of nine known reference compounds (2,
5−6, 8−9, and 29) were included for comparison.10,14 Standard
assays of potency for activation of PLC were performed as
described26 in 1321N1 human astrocytoma cell lines stably
expressing either the P2Y2R, P2Y4R, or P2Y6R (1321N1-P2YR
cells).
Among substituted phenyl groups, 3-F 12, 4-I 16, and 4-
MeO 19 provided relatively high potency at the three P2Y2,
P2Y4, and P2Y6Rs. Thus, we decided to elongate functionalized
congeners based on p-substituted ethers related to 19. Other
aryl moieties that appeared to enhance potency were thien-3-yl
22 and naphth-2-yl 23, indicating a tolerance of steric bulk in
this region. The optimal chain length at the P2Y4R was reached,
with the n-propyl analogue 2 not substituted with an ether in
the chain (cf. 11). In contrast, the longer n-butyl homologue 10
displayed increased potency at the P2Y2R and P2Y6R. High
potency at the P2Y4R was achieved with a terminal alkyne at
the N4-linked chain for tethering sterically bulky groups by click
chemistry (26, EC50 = 40 nM, Figure 1). However, potency at
P2Y2R and P2Y6R also was largely retained in this ether- and
amide-linked alkyne, with EC50 values of 109 and 183 nM,
respectively.
Scheme 3. Synthesis of Fluorescent 4-Alkoxyiminopyrimidine Ribonucleoside 5′-Triphosphates 27 and 28 by Click Reaction
with Azido-Dyesa
aReagents and conditions: (a) azide (e.g., 124, 1 equiv) and alkyne (1.4 equiv) precursors, tBuOH/water, TBTA, sodium ascorbate, cupric sulfate.
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The fluorescent dye, Alexa Fluor 488, is a suitable
fluorophore for flow cytometry (FCM) binding assays and
live cell imaging.14,18 This fluorophore was incorporated in
conjugate 27, but only an intermediate potency was observed
with this molecule at the three P2YRs. An alternative BODIPY
630/650 fluorophore was incorporated in conjugate 28.
Curiously, in comparison to the precursor molecule 26, the
BODIPY conjugate exhibited enhanced potency at the P2Y2R
(EC50 = 66 nM) and P2Y6R (EC50 = 23 nM) but slightly
decreased potency at the P2Y4R. Thus, 28 is a high affinity pan-
agonist fluorescent probe with nearly equivalent potency at the
hP2Y2R, hP2Y4R, and hP2Y6R.
A preliminary feasibility study was carried out to determine if
28 could serve as a fluorescent P2YR probe. These experiments
were with P2Y6R-expressing 1321N1 cells because 28 is most
potent at this P2YR subtype (Figure 2). Fluorescent binding of
28 was compared by FCM, using several known P2Y6R ligands
to compete for cell labeling. Incubation of cells with 100 nM 28
for 30 min at 37 °C in the presence of the ecto-nucleotidase
inhibitor α,β-methylene-adenosine 5′-diphosphate 125 (100
μM)33,34 resulted in significant cell labeling (Figure 2). The
level of cell-associated fluorescence was not reduced by
coincubation of 28 with 10 μM N6-methyl-2-deoxyadenosine
3,5′-bisphosphate (117, MRS2179), a P2Y1R-selective antago-
nist that is inactive at P2Y2, P2Y4, and P2Y6Rs.
28 However,
significant decreases in mean fluorescence intensity were
observed after preincubation with P2Y6R ligands, including
the P2Y6R-selective noncompetitive antagonist N,N″-1,4-
butanediyl-bis[N′-(3-isothiocyanatophenyl)]thiourea (118,
MRS2578, 10 μM) and the competitive antagonist suramin
(119, 10 μM).29,30 Although 119 is a nonselective P2X and
P2Y antagonist, we included it in this assay because it has been
shown to effectively block the P2Y6R.
26 The potent P2Y6R-
selective dinucleotide agonist P1-(uridine 5′-)-P4-(N4-methox-
ycytidine 5′-)triphosphate (120, MRS2957, 10 μM)14
produced the largest decrease in cell-associated fluorescence.
Fluorescence microscopy comparing binding to 1321N1-P2Y6R
cells in the presence and absence of 118 (Figure 3) indicated
that 1 μM 28 specifically labeled cells expressing the receptor.
■ DISCUSSION
We have identified a functionalization approach that provides
versatile nucleotide analogues for further derivatization of high
potency P2Y2R, P2Y4R, and P2Y6R agonists. The initial
approach was based on a P2Y4R-selective agonist, and many
of the new derivatives tend toward selectivity at this subtype.
However, upon elongation of a functionalized chain at the N4
Scheme 4. Synthesis of N-Alkoxyamines: (A) 3-Phenylpropyl and 3-(naphth-2-yl)propyl Intermediates Prepared by the Gabriel
Synthesis.25 (B) N-Alkoxyamine Intermediates Prepared Using N,N′-di-tert-Butoxycarbonylhydroxylamine as Describeda
aReagents and conditions: (A) (a) diethyl malonate, NaH, THF; (b) NaCl, DMSO; (c) DiBal-H; (d) CBr4, PPh3; (e) Et3N, DMF, 100°C; (f)
NH2NH2·H2O; (g) 1 N HCl. Protected 3-(4-carboxymethyloxy-phenyl)propyl (91) and 3-(thien-3-yl)propyl (92). N-alkoxyamine intermediates
were prepared by analogous methods (Scheme S1, Supporting information): (a) K2CO3, CH3CN, reflux; (b) CBr4, PPh3; (c) Et3N, DMF, 100 °C;
(d) NH2NH2·H2O; (e) 10% Pd/C, H2, MeOH; (f) LiAlH4, THF; (g) Br2, PPh3, 2,6-lutidine.
22 (B) (a) HBr in acetic acid, 50 °C; (b) DBU, CH3CN,
50 °C; (c) 1 N HCl, CH2Cl2.
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position, significant potency also was observed at the related
P2Y2R and P2Y6R subtypes. For example, compound 19 was
particularly potent at P2Y2 and P2Y4Rs.
The derivatization strategy was aimed to clarify where to
modify the pyrimidine nucleotides to preserve or increase
potency at any or all of the relevant P2YRs to allow the
attachment of sterically large fluorophores27 and other reporter
groups. Questions to be answered were: If the pseudo-oxime
chain of 2 proved to be a suitable attachment point, how long
should the alkyl linker (i.e., propyl in 2) be for optimal potency
(cf. 8, 9, 11, 25)? Were ring-substitutions (cf. 12−19) or
replacement of the terminal phenyl moiety with heteroaryl or
other group (cf. 7, 20−24) desirable for enhancing potency?
What position for attachment of an elongated chain on the
phenyl (cf. 12−19) or other aryl group was best suited for high
potency? Thus, model compounds of various intermediate
substructures were prepared and tested before the final target
fluorescent conjugates were designed. Briefly, we chose the p-
Figure 1. Comparison of potencies of alkyne 26 and fluorescent
analogues 27 and 28 in activation of PLC via the human P2Y2R (A),
P2Y4R (B), and P2Y6R (C) in stably transfected 1321N1 human
astrocytoma cells.
Figure 2. Fluorescence ligand binding experiments using FCM in
stably transfected 1321N1-P2Y6R cells with 28 after preincubation at
37 °C with known P2Y6R agonist or P2Y6R antagonists. Each column
shows the brightness of each compound using 28 set at 100% and after
correcting the MFI values for autofluorescence. Results are expressed
as mean ± SEM (n = 4). Binding of 28 at 20 and 30 min to the P2Y6R
was significantly blocked after preincubation with selective antagonist
118, selective agonist 120, and nonselective antagonist 119. No
significant difference in MFI was observed for P2Y1R antagonist 117.
*, p < 0.05, when compared to cells treated with only 28. Average of
MFI after 20 min incubation of 28: 107.0 ± 30.2; after 30 min
incubation of 28: 222.8 ± 72.1.
Figure 3. Fluorescent micrographs using a Keyence fluorescent
microscope (BZ-9000) of P2Y6R-expressing 1321N1 astrocytoma cells
exposed to the fluorescent agonist 28 (1 μM, 30 min incubation at 37
°C). (A) Control cells in the absence of 14. (B) Incubation with 1 μM
14 at 37 °C for 30 min in medium. (C) Incubation with 1 μM 14 at 37
°C for 30 min in cells pretreated with noncompetitive antagonist 118
(10 μM).
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position for extension of an alkyl ether chain on the 4-(3-
phenylpropyloxy)imino group of 2, which was click-linked20
through a terminal alkyne, i.e., 26, to an azide-bearing
fluorophore. Other possible approaches could have been
through chain elongation at the 2, 3, or 5 positions of a uracil
ring.13,21
Modifications of the distal phenyl ring of a 3-phenyl-
propyloxyimino group, shown previously to be optimal for
P2Y4R potency, allowed a bulky fluorescent reporter group to
be introduced, but the P2Y4R selectivity was compromised.
Nevertheless, these molecules also provide high affinity leads
for further modified agonists that could exhibit higher
selectivity at one of these receptors. Possible directions for
structural modifications of pyrimidine nucleotides conducive to
P2Y4R selectivity might include ribose and nucleobase
modifications such as appear in compounds 3 and 4.
This discovery provides an optimal new route for generation
of fluorescent probes for facile pooled quantification of these
three P2YRs in living cells. In cells expressing a single P2YR
subtype, such as our astrocytoma cells, there is no ambiguity.
Following the development of standard assay conditions, the
potent fluorescent ligand 28 could potentially be used for high-
throughput screening of drug libraries with P2Y2R-, P2Y4R-, or
P2Y6R-expressing cells. Radioligands are not available for any of
these receptors. Our previously reported fluorescent nucleotide
P2YR probe, a conjugate of Alexa Fluor 488, tethered from a
cytosine nucleobase in the diphosphate series, was selective for
the P2Y6R.
14 The current work adds a second viable fluorescent
probes for studying the P2Y6R. Although we did not directly
examine its binding to P2Y2R- and P2Y4R-expressing cells,
compound 28 adds the potential capability of fluorescent
characterization of these subtypes for which no high affinity
assay probes are available. Assay development for routine
application of this fluorescent probe presents a separate
experimental challenge that will be addressed in future work.
The high potency of 28 at the hP2Y2R, hP2Y4R, and hP2Y6R
suggests the existence of energetically favorable interactions
with groups on the conformationally flexible extracellular
regions of P2Y2R and P2Y6R. The modeling of these
extracellular regions is difficult because of their flexibility and
the lack of a close structural template. Further characterization
of the location of the fluorescent label within the cells as well as
delineation of the saturability, reversibility, kinetics, and other
measurements will be required before this probe molecule can
be used routinely for FCM labeling of cells expressing P2YRs.
■ CONCLUSIONS
A series of N4-(3-arylpropyloxy) derivatives of uridine-5′-
triphosphate were synthesized and found to display high
potency as agonists of the initial target G protein-coupled
hP2Y4R and also hP2Y2R and hP2Y6R. The phenyl group could
be substituted with heterocyclic rings or a naphthyl ring with
retention of P2YR affinity, indicating a broad tolerance for
steric bulk in this distal region of the nucleotide. Thus, an
extended N4-(3-arylpropyloxy) group accessed a structurally
permissive region on various Gq-coupled P2YRs and was
modulated by distal structural changes to alter selectivity. This
freedom of substitution can be utilized for the design of pan-
agonist affinity probes of the uracil nucleotide-activated, Gq-
coupled P2Y2/4/6 subset of receptors.
■ EXPERIMENTAL SECTION
Chemical Synthesis. 1H NMR spectra were obtained with a
Varian Mercury 400 spectrometers using D2O, MeOD, CDCl3, or
DMSO-d6 as a solvent. The chemical shifts are expressed as relative
ppm from HOD (4.80 ppm). 31P NMR spectra were recorded at room
temperature (rt) on Varian Mercury 400 (162.10 MHz) spectrom-
eters; orthophosphoric acid (85%) was used as an external standard. In
several cases, the signal of the terminal phosphate moiety was not
visible due to high dilution. High-resolution mass measurements were
performed using a Micromass/Waters LCT Premier Electrospray time
of flight (TOF) mass spectrometer coupled with a Waters HPLC
system, unless noted. Alexa Fluor 488 azide was from Invitrogen
(Carlsbad, CA). All other reagents were of analytical grade and were
purchased from Sigma-Aldrich (St. Louis, MO).
Purification of the nucleotide analogues for biological testing was
carried out on (diethylamino)ethyl (DEAE)-A25 Sephadex columns
with a linear gradient (0.01−0.5 M) of 0.5 M ammonium bicarbonate
as the mobile phase. Then these nucleotides were additionally purified
by HPLC with a Luna 5 μ RP-C18(2) semipreparative column (250
mm × 10.0 mm; Phenomenex, Torrance, CA) and using the following
conditions: flow rate of 2 mL/min; 10 mM triethylammonium acetate
(TEAA)-CH3CN from 100:0 to 95:5 (system B) (or up to 99:1 to
50:50 (system C)) in 30 min (and isolated in the triethylammonium
salt form). All other compounds (cytidine derivatives) were purified
from a silica column chromatography (CHCl3:MeOH-gradient from
100:0 to 70:30). Purity of the compounds submitted for bioassay was
checked using a Hewlett−Packard 1100 HPLC equipped with a
Zorbax SB-Aq 5 μm analytical column (50 mm × 4.6 mm; Agilent
Technologies Inc., Palo Alto, CA). Mobile phase: linear gradient
solvent system; 5 mM TBAP (tetrabutylammonium dihydrogenphos-
phate)-CH3CN from 80:20 to 40:60 in 13 min; the flow rate was 0.5
mL/min (system A). Peaks were detected by UV absorption with a
diode array detector at 230, 254, and 280 nm. All nucleotide
derivatives tested for biological activity showed >98% purity by HPLC
analysis (detection at 254 nm).
General Procedure for the Preparation of Nucleoside
Triphosphates (7, 10−26). A solution of the nucleoside 97−112,
114 (73.0 μmol), and 1,8-bis(dimethylamino)naphthalene (Proton
Sponge, 24.0 mg, 0.11 mmol) in trimethyl phosphate (0.4 mL) was
stirred for 10 min at 0 °C.15 Then, phosphorus oxychloride (13.0 μL,
0.13 mmol) was added dropwise, and the reaction mixture was stirred
for 2 h at 0 °C. A solution of tributylammonium pyrophosphate (0.80
mL, 0.44 mmol) and tributylamine (69.0 μL, 0.29 mmol) in N,N-
dimethylformamide (DMF, 1 mL) was added, and stirring was
continued at 0 °C for additional 10 min. Then 0.2 M
Triethylammonium bicarbonate solution (1.5 mL) was added, and
the clear solution was stirred at rt for 1 h. After removal of solvents,




(26). Compound 26 (7.0 mg, 6.9 μmol, 10%) was obtained as a
white solid using N4-(3-((4-but-3-yn-1-aminocarbonylmethyleneoxy)-
phenyl)propyloxy)cytidine 116 (35.5 mg, 70.1 μmol). 1H NMR
(D2O) δ 7.27−7.19 (m, 3H), 6.94 (d, J = 8.6, 2H), 5.94 (d, J = 6.4 Hz,
1H), 5.77 (d, J = 8.2, 1H), 4.60 (s, 2H), 4.44−4.40 (m, 1H), 4.36 (t, J
= 5.9, 1H), 4.26−4.14 (m, 3H), 4.06 (t, J = 6.0, 2H), 3.44 (t, J = 6.6,
2H), 2.75−2.63 (m, 2H), 2.44 (dt, J = 6.6, J = 2.7, 2H), 2.33 (t, J = 2.6,
1H), 2.07−1.91 (m, 2H). HRMS-EI found: 741.0974 (M − H+)−.




phosphate Triethylammonium Salt (27). To a mixture of Alexa
Fluor 488 azide (Alexa Fluor 488 5-carboxamido-(6-azidohexanyl),
bis(triethylammonium salt)), 5-isomer, 0.5 mg, 0.8 μmol, 1 equiv), and
alkyne 26 (0.8 mg, 0.8 μmol, 1.4 equiv) in a 0.20 mL of (1:1) mixture
of tBuOH and water, were added tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl] amine (TBTA, 0.1 mg) and freshly prepared 1 M aqueous
sodium ascorbate solution (1.6 μmol, 1.6 μL, 2 equiv) followed by
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7.5% aqueous copper sulfate pentahydrate solution (4.0 μL, 1.2 μmol,
1.5 equiv). The reaction mixture was stirred overnight at rt, solvent
was evaporated, and the residue was purified by semipreparative
HPLC as described above to obtain 27 (1.64 mg, 34% yield) as a




nium Salt (28). To a mixture of BODIPY 630/650 azide (124,
Supporting Information, 1.0 mg, 1.0 μmol, 1 equiv) and alkyne 26 (2.0
mg, 1.8 μmol, 1.2 equiv) in a 200 μL of (1:1) mixture of tBuOH and
water, and 20 μL of DMF, were added tris[(1-benzyl-1H-1,2,3-triazol-
4-yl)methyl] amine (TBTA, 0.05 mg) and freshly prepared 1 M
aqueous sodium ascorbate solution (1.1 μL, 1.6 μmol, 1 equiv)
followed by 7.5% aqueous copper sulfate pentahydrate solution (2.5
μL, 0.8 μmol, 0.8 equiv). The bright-blue color reaction mixture was
stirred overnight at rt, solvent was evaporated, and the residue was
purified by semipreparative HPLC as described above to obtain
desired triphosphate 28 as blue-colored solids. HRMS-EI m/z (M +
ES MS) for 28 found, 1388.3648 (M + H+)+; calcd for
C64H68N11O20BF2P3S, 1388.3631; analytical HPLC (system A: 7.91
min). Fluorescence absorption and emission spectra indicated max
values at 634 and 650 nm, respectively (Supporting Information), as
measured in solution in a cuvette using a SpectraMax M5 reader
(Molecular Devices, Sunnyvale, CA).
General Synthesis of P1-(N4-Phenylpropoxycytidine-5′-)P4-
(uridine-5′-)-tetraphosphate Triethylammonium Salt (30).
Uridine 5′-monophosphate disodium salt (4.4 mg, 11.0 μmol, 2
equiv) and N4-(3-phenylpropoxy)cytidine-5′-triphosphate triethylam-
monium salt 2 (4.5 mg, 5.4 μmol, 1 equiv) were converted to the
tributylammonium salts by treatment with ion-exchange resin
(DOWEX 50WX2-200 (H)) and tributylamine. After removal of the
water, the obtained uridine monophosphate dibutylammonium salt
and the tributylammonium salt of N4-phenylpropoxycytidine-5′-
triphosphate 2 (4.5 mg, 5.5 μmol, 1 equiv) were dried under high
vacuum for 1 h in separate vials. DIC (1 μL, 5.5 μmol, 1 equiv) was
added to a solution of N4-(3-phenylpropoxy)cytidine-5′-triphosphate
tributylammonium salt 2 in DMF (200 μL). After stirring the reaction
mixture at rt for 3 h, a solution of the uridine 5′-monophosphate
tributylammonium salt (11.0 μmol) and MgCl2 (1.0 mg, 11.0 μmol, 2
equiv) in DMF (100 μL) were added. The reaction mixture was stirred
at rt overnight. After removal of the solvent, the MgCl2 was removed
by treatment with ion-exchange resin (DOWEX 50WX2-200 (H)) and
ammonia bicarbonate or tri-n-butylamine, and the residue was purified
by a semipreparative HPLC purification using system C. Compound
30 (1.0 mg, 0.8 μmol, 16%) was obtained as a white solid. 1H NMR
(D2O) δ 7.93 (d, J = 7.9 Hz, 1H), 7.35−7.30 (m, J = 8.3 Hz, 4H),
7.25−7.21 (m, 2H), 6.02−5.91 (m, 2H), 5.78 (d, J = 7.9 Hz, 1H),
4.42−4.33 (m, 4H), 4.30−4.16 (m, 6H), 4.05 (t, J = 4.8 Hz, 2H), 2.74
(t, J = 8.3 Hz, 2H), 2.05−1.79 (m, 2H). 31P NMR (D2O) δ −11.51
(br), −23.22 (br). HRMS-EI found: 922.0742 (M − H+)−.
C27H36N5O23P4 requires 922.0752; analytical HPLC (system A: 7.92
min).
P1 - (N 4 - (3 -Pheny lpropoxy )cy t id ine -5 ′ - )P 4 - (N 4 - (3 -
phenylpropoxy)cytidine-5′-)-tetraphosphate Triethylammo-
nium Salt (31). Compound 31 (0.5 mg, 0.3 μmol, 10%) was
obtained as a white solid using N4-(3-phenylpropoxy)cytidine-5′-
triphosphate triethylammonium salt (3.0 mg, 3.0 μmol) and N4-(3-
phenylpropoxy)cytidine-5′-monophosphate diethylammonium salt
(3.0 mg, 6.1 μmol) from the previous procedure. 1H NMR (D2O) δ
7.45−7.10 (m, 12H), 5.95−5.87 (m, 2H), 5.79−5.63 (m, 2H), 4.39−
4.29 (m, 4H), 4.27−4.16 (m, 6H), 4.06−4.00 (m, 4H), 2.80−2.65 (m,
4H), 2.05−1.93 (m, 4H). HRMS-EI found: 1055.1593 (M − H+)−.
C36H47N6O23P4 requires 1055.1643; analytical HPLC (system A: 9.10
min).
Synthesis of compounds 40−96 is described in the Supporting
Information.
General Procedure for the Synthesis of N4-Alkoxycytidine
analogues (97−110, 113) N4-(4-Phenylbutyloxy)cytidine (97).
A suspension of cytidine (360 mg, 1.5 mmol) and 4-phenylbutoxy-
amine hydrochloride (87, 617 mg, 3.0 mmol, 2 equiv) in pyridine (4
mL) was stirred at 100 °C overnight. The reaction mixture was
evaporated, and the residue was evaporated twice with toluene,
triturated with chloroform, and filtered. The filtrate was evaporated,
and the residue was purified by flash chromatography (chloroform−
methanol, gradient of 3−10%) to afford N4-(4-phenylbutyloxy)-
cytidine (97) (0.430 g, 1.10 mmol, 73%). 1H NMR (400 MHz,
MeOD): 7.52 (d, J1 = 8.20 Hz, 1H), 7.20−7.17 (m, 2H), 7.15−7.05
(m, 3H), 5.83 (d, J1 = 4.84 Hz, 1H), 5.63 (d, J1 = 8.12 Hz, 1H), 4.13
(t, J1 = 5.20 Hz, 1H), 4.09 (m, 1H), 4.00−3.92 (m, 3H), 3.78 (dd, J1 =
12.16 Hz, J1 = 2.72 Hz, 1H), 3.68 (dd, J1 =12.20 Hz, J2 = 3.16 Hz, 1H),
2.60 (t, J1 = 6.88 Hz, 2H), 1.70−1.60 (m, 4H). 13C NMR (400 MHz,
MeOD): 149.2, 147.6, 142.0, 137.1, 135.0, 128.0, 127.9, 125.4, 95.0,
88.9, 84.8, 74.4, 73.7, 69.9, 60.9, 35.1, 27.7, 27.3. m/z (M + ESI MS)
found, 392.1813; calcd for C19H26N3O6, 392.1816.
N4- (3-( (4- tert -Butyloxy-carbonylmethoxy)phenyl) -
propyloxy)cytidine (115). Compound 115 (45 mg, 88.5 μmol,
65%) was obtained as a white solid from cytidine (29 mg, 0.12 mmol)
and N4-(3-(4-tert-butyloxy-carbonylmethoxy)phenyl)propyloxyamine
hydrochloride (91) (79 mg, 0.25 mmol) using the above procedure.
1H NMR (400 MHz, MeOD): 7.16 (d, J1 = 8.24 Hz, 1H), 7.06 (d, J1 =
8.36 Hz, 2H), 6.76 (d, J1 = 8.52 Hz, 1H), 5.82 (d, J1 = 5.20 Hz, 1H),
5.55 (d, J1 = 8.24 Hz, 1H), 4.46 (s, 2H), 4.13−4.10 (m, 2H), 3.94−
3.91 (m, 3H), 3.76 (d, J1 = 12.08 Hz, 1H), 3.66 (dd, J1 =12.12 Hz, J2
=3.00 Hz, 1H), 2.58 (t, J1 = 7.08 Hz, 2H), 2.01−1.86(m, 2H), 1.42(s,
9H). 13C NMR (400 MHz, MeOD): 169.0, 156.2, 150.1, 144.7, 134.7,
131.4, 129.1, 114.2, 97.6, 88.4, 84.6, 82.0, 73.4, 72.8, 70.3, 65.4, 61.3,
30.8, 30.4, 27.0. m/z (M + ESI MS) found, 508.2294; calcd for
C24H34N3O9, 508.2290.
N4-(3-(((But-3-ynyl-1-amino)-4-methoxycarbonyl)phenyl)-
propy loxy )cyt id ine (116) . N 4 - (3 - ( (4 - t e r t -Bu ty loxy -
carbonylmethoxy)phenyl)propyloxy)cytidine 115 (44 mg, 0.12
mmol) was dissolved in 1.0 mL of THF and treated with 2.0 mL of
1 N NaOH. The reaction mixture was stirred at 50 °C for 2 h. The
mixture was cooled to rt and neutralized by adding 1N HCl. After
removal of the solvent, N4-(3-((4-methoxycarbonate)phenyl)-
propyloxy)cytidine (31 mg, 68 μmol, 56%) was isolated after column
chromatography. 1H NMR (400 MHz, MeOD): 7.17 (d, J1 = 8.24 Hz,
1H), 7.09 (d, J1 = 8.44 Hz, 2H), 6.81 (d, J1 = 8.64 Hz, 1H), 5.82 (d, J1
= 5.44 Hz, 1H), 5.55 (d, J1 = 8.24 Hz, 1H), 4.57 (s, 2H), 4.12 (t, J1 =
5.40 Hz, 1H), 4.08 (m, 1H), 3.95−3.90 (m, 3H), 3.74 (dd, J1 = 12.08
Hz, J1 = 2.88 Hz, 1H), 3.66 (dd, J1 = 12.16 Hz, J2 = 3.40 Hz, 1H), 2.60
(t, J1 = 7.40 Hz, 2H), 1.95−1.86 (m, 2H). 13C NMR (400 MHz,
MeOD): 156.2, 150.1, 144.7, 134.7, 131.3, 129.0, 114.1, 97.4, 88.3,
84.7, 73.3, 72.7, 70.3, 64.6, 61.3, 30.8, 30.4, 27.0. m/z (M + ESI MS)
found, 442.1665; calcd for C20H26N3O9, 452.1664.
The above isolated acid (50 mg, 0.1 mmol), DIEA (0.128 mL, 0.93
mmol, 8.5 equiv), and 6.0 mL of DMF were added to round-bottom
flask. Then 4-amino-1-butyne (13.5 μL, 0.16 mmol, 1.5 equiv) and 1.0
mL of DMF were added to the above mixture, which was then stirred
for 10 min at rt. PyBOP (57 mg, 0.11 mmol, 1.1 equiv) was added, and
the mixture was stirred overnight. Solvent was removed, and 116 (45.1
mg, 89.9 μmol, 80%) was isolated following column chromatography.
1H NMR (400 MHz, MeOD): 7.17 (d, J1 = 8.28 Hz, 1H), 7.11 (d, J1 =
8.56 Hz, 2H), 6.86 (d, J1 = 8.64 Hz, 2H), 5.82 (d, J1 = 5.44 Hz, 1H)
5.53 (d, J1 = 8.24 Hz, 1H), 4.43 (s, 2H), 4.15−4.00 (m, 2H), 3.95 (t, J1
= 6.36 Hz, 2H), 3.91 (q, J1 = 3.32 Hz, 1H), 3.75 (dd, J1 = 12.16 Hz, J1
= 2.88 Hz, 1H), 3.66 (dd, J1 = 12.12 Hz, J2 = 3.36 Hz, 1H), 3.38 (t, J1
= 7.08 Hz, 2H), 2.62 (t, J1 = 7.40 Hz, 2H), 2.37 (td, J1 = 7.08 Hz, J1 =
2.64 Hz, 2H), 2.25 (t, J1 = 2.64 Hz, lH), 2.01−1.85 (m, 2H). 13C
NMR (400 MHz, MeOD): 170.11, 155.98, 150.03, 144.68, 135.27,
131.37, 12 129.5, 123.9, 114.7, 114.5, 112.1, 111.9, 97.4, 88.3, 84.7,
73.3, 72.5, 70.3, 61.3, 31.4, 30.1. m/z (M + H ESI MS) found,
503.2139; calcd for C24H31N4O8, 503.2136.
Procedures for Phospholipase C Assay. Stable cell lines for
study of the human (h) P2Y2, P2Y4, and P2Y6Rs were produced by
retroviral expression of the individual receptors in 1321N1 human
astrocytoma cells, which do not natively express P2YRs.31 Agonist-
stimulated [3H]inositol phosphate accumulation was quantified in cells
plated at 20000 cells/well on 96-well plates two days prior to assay.
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The inositol lipid pool of cells was radiolabeled 16 h prior to the assay
by incubation with 100 μL of serum-free inositol-free Dulbecco’s
Modified Eagle’s Medium, containing 1.0 μCi of [3H]myo-inositol. No
changes of medium were made subsequent to the addition of
[3H]inositol. Test drugs were added in 25 μL of 100 mM Hepes (N-
(2-hydroxyethyl)-piperazine-N′-2-ethanesulfonic acid), pH 7.3, in
HBSS containing 50 mM LiCl. Incubations were for 30 min at 37
°C and were terminated by aspiration of the drug-containing medium
and addition of 90 μL of ice-cold 50 mM formic acid. The samples
were neutralized with 30 μL of 150 mM NH4OH and applied to
Dowex AG1-X8 anion exchange columns. Total inositol phosphates
were eluted, and radioactivity was measured using a liquid scintillation
counter.26
Data Analysis. Agonist potencies (EC50 values) were determined
from concentration−response curves by nonlinear regression analysis
using the GraphPad software package Prism (GraphPad, San Diego,
CA). Each concentration of drug was tested in triplicate assays, and
concentration effect curves for each test drug were repeated in at least
three separate experiments with freshly diluted molecule. The results
are presented as mean ± SEM from multiple experiments or in the
case of concentration effect curves from a single experiment carried
out with triplicate assays that were representative of results from
multiple experiments.
Cell Cultures for FCM. 1321N1 human astrocytoma cells
overexpressing the P2Y6R were grown in DMEM with 5% FBS, 50
U/mL penicillin/streptomycin, and 2 mM L-glutamine. Cells were
grown in 6-well plates (approximately 3 × 105 cells/well) and
incubated at 37 °C and 5% CO2 for 24 h. At 80% confluency, the
medium was replaced with fresh preheated medium, in addition to α,β-
methylene-adenosine 5′-diphosphate (125, AMP-CP, 100 μM) and a
known agonist or antagonist of the P2Y6R. After a 30 min incubation,
28 was added at different time intervals and the decrease in
fluorescence intensity was measured by FCM.
Fluorescent Ligand Binding in 1321N1 Astrocytoma Cells
Expressing P2Y6R. Binding of 28 to the P2Y6R in overexpressing
1321N1 astrocytoma cells was blocked by using known P2Y6R ligands,
such as antagonists 118 and 119 or the agonist 120 (all 10 μM). Ecto-
nucleotidase inhibitor 125 (100 μM) was added to prevent the
metabolism of 5′-di and triphosphate derivatives to the 5′-mono-
phosphates.32−,34 After a 30 min preincubation with the appropriate
agonist or antagonist and 125 (100 μM), 28 (100 nM) was added at
different time intervals from 20 to 30 min. At the end of incubation,
the medium was removed, the cells were washed three times with ice-
cold DPBS, and 1 mL of 0.2% EDTA was added to each well to detach
the cells from the plate. Cells were then incubated at 37 °C for 5−10
min. After detaching, 1 mL of medium was added to neutralize the
EDTA. The cell suspensions were transferred to 5 mL of polystyrene
round-bottom BD Falcon tubes (BD, Franklin Lakes, NJ) and
centrifuged for 5 min at 23 °C and 400g. After the supernatant was
discarded, the cells were washed with 3 mL of DBPS and centrifuged
again at 23 °C and 400g for 5 min. After centrifugation, the
supernatant was discarded and the cells suspended in 0.5 mL of DPBS
for analysis by FCM.
FCM Analysis. The intensity of fluorescence emission of each
sample was measured by using FCM. Cell suspensions were vortexed
briefly before analysis on a Becton and Dickinson FACSCalibur flow
cytometer (BD, Franklin Lakes, NJ). Samples were maintained in the
dark during the analysis to avoid photobleaching. Measured
fluorescent intensities (MFIs) were obtained in the FL-4 channel in
log mode. Ten thousand events were analyzed per sample. Data were
collected and analyzed using Cell Quest Pro software (BD, Franklin
Lakes, NJ).
Fluorescent Microscopy Studies. P2Y6R-expressing astrocytoma
cells were grown on glass coverslips placed in a 6-well plate. When the
cells reached 80% confluence, the medium was replaced with fresh
medium, P2Y6R antagonist 118 (10 μM) was added to the cells, and
incubation was continued for 30 min at 37 °C. Then 16 was added to
achieve a final concentration of 1 μM, and incubation continued for 30
min at 37 °C. At the end of the incubation, the cells were washed with
ice-cold PBS and mounted on a glass slide. The cells were visualized
using a Keyence BZ-9000 fluorescent microscope.
Data Analysis. Data analysis was performed with the Prism 5
(GraphPad, San Diego CA) software. The mean autofluorescence of
1321N1 astrocytoma cells was measured in the absence of the
fluorescent ligand. The mean fluorescence intensity in the presence of
fluorescent ligand was corrected by subtracting the autofluorescence.
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